MedPacto, Inc. (KOSDAQ: 235980)

South Korea flag South Korea · Delayed Price · Currency is KRW
4,560.00
-90.00 (-1.94%)
Dec 19, 2024, 9:00 AM KST
-33.53%
Market Cap 148.59B
Revenue (ttm) n/a
Net Income (ttm) -23.31B
Shares Out 33.58M
EPS (ttm) -761.83
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 128,592
Open 4,585.00
Previous Close 4,650.00
Day's Range 4,470.00 - 4,630.00
52-Week Range 4,000.00 - 17,240.00
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date Mar 19, 2025

About MedPacto

MedPacto, Inc., a drug discovery and development company, develops and delivers therapeutics targeting cancer and autoimmune diseases in South Korea. The company is developing ME-1601mAb that targets BSP1 for cancers; MS-1601A that targets TRG1 for cancers and autoimmune diseases; and vactosertib for solid tumors. MedPacto, Inc. is based in Seoul, South Korea. [Read more]

Industry Biological Products, Except Diagnostic Substances
CEO Seong-Jin Kim
Employees 56
Stock Exchange KOSDAQ
Ticker Symbol 235980
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.